[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"primary-progressive-aphasia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:primary-progressive-aphasia":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,44,79,129,155,184,210,236,274,299,325,357,381,400,423],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100641698","stimulating-the-aging-brain-using-brain-and-sensory-stimulation-100641698",false,"NCT07650188","Stimulating the Aging Brain Using Brain and Sensory Stimulation","Stimulating the Aging Brain: Noninvasive Brain and Sensory Stimulation Strategies in Aging","StAB","Inclusion Criteria:\n\n* Clinical exam supports diagnosis of PPA and\u002For MCI with no report of difficulty functioning in basic or instrumental activities of daily living.\n* Completed clinical cognitive exam within 6 months of study baseline visit OR neuropsychological research battery within 6 months of study baseline visit.\n\nExclusion Criteria:\n\n* Evidence of dementia at baseline\n* Known history of neoplasm, symptomatic stroke, moderate to severe traumatic brain injury, or other significant neurologic event\n* Age \\\u003C45 years.\n* Evidence of severe psychiatric illness (e.g., bipolar disorder, schizophrenia).\n* Presence of cardiac stimulators or pacemakers\n* Any other implants near the scalp or in the eye\n* Contraindications to MRI or stimulation\n* Pregnancy\n* History of ongoing or unmanaged seizures\n* History of dyslexia or other developmental learning disabilities","ALL","45 Years",{"count":20,"type":21},20,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this project is to investigate whether transcranial electrical stimulation and sensory stimulation affect language outcomes in individuals with primary progressive aphasia (PPA). The main questions it aims to answer are:\n\nDoes transcranial alternating current stimulation (tACS) affect verbal short-term memory (STM) in individuals with PPA? Does a single session of multisensory stimulation affect verbal STM in individuals with PPA? Researchers will compare active tACS to sham tACS (a fake stimulation condition) to see if active tACS improves verbal STM. Researchers will compare pre-multisensory stimulation to post-stimulation performance to see if multisensory stimulation improves verbal STM.\n\nParticipants will:\n\nUndergo EEG, MRI (anatomical and functional) May complete a cognitive exam Undergo tACS over 3 separate sessions Undergo multisensory stimulation Complete language tasks before, during and\u002For after stimulation",[27],"Primary Progressive Aphasia",[29,30],"Transcranial alternating current stimulation","Multisensory stimulation","RECRUITING","2026-06-11",{"date":34,"type":35},"2026-06-16","ACTUAL",{"date":37,"type":35},"2026-06-01",{"date":39,"type":21},"2035-05-30",{"name":41,"class":42},"Medical College of Wisconsin","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":51,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":57,"conditions":58,"keywords":64,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":43},"100555412","early-phase-1-educational-support-group-program-for-bilingual-and-spanish-speaking-carepartners-and-people-with-progressive-aphasia-100555412","NCT06511752","Educational Support Group Program for Bilingual and Spanish-speaking Carepartners and People With Progressive Aphasia","Educational Support Group Program for Carepartners of Bilingual and Spanish-speaking Persons With Progressive Forms of Aphasia and for Persons With Progressive Forms of Aphasia","Inclusion Criteria:\n\nAll participants must:\n\n* speak Spanish and\u002For English (although participants may speak other languages in addition to Spanish and\u002For English)\n* identify as Hispanic and\u002For Latinx,\n* or their spouse\u002Ffamily member with PA identifies as Hispanic and\u002For Latinx\n* see and hear well enough to participate\n* have access to a computer or mobile device with video capability\n* have an internet connection\n\nAdditional inclusion criteria for PA\u002F language-led dementia support group participants:\n\n* Individuals with PA:\n* Has a diagnosis of PA, or language-led dementia, and aphasia is one of the primary causes of difficulty with activities of daily living\n* Aware of language difficulties and willing to discuss them\n* Able to actively engage in group discussion and complete activities with minimal support\n* Able to regularly attend meetings\n* Willing to follow the rules of the support group for interacting with others respectfully\n\nAdditional inclusion criteria for care partner support group plus implementation phase participants:\n\n* Individuals with PA:\n* Diagnosis of aphasia or dementia that is progressive in nature, and aphasia is one of the primary causes of difficulty with activities of daily living\n* Have some ability to communicate and understand communication in order to participate in training sessions\n* Are functionally able to engage in training sessions (e.g., able to maintain some attention, minimal challenging behavior that would cause disruption)\n* Have a care partner who also consents to participating in the project\n* Care partners:\n* Self-identification as a caregiver of an individual with a diagnosis of PA or language-led dementia\n* Willing to discuss caregiving for individuals with PA\u002F language-led dementia\n* Able to regularly attend meetings\n* Willing to follow the rules of the support group for interacting with others respectfully\n\nExclusion Criteria:\n\n• Beyond the inclusion criteria included above, no additional exclusion criteria apply",true,"18 Years",{"count":54,"type":21},120,[56],"EARLY_PHASE1","The current study aims to examine the benefits of an education\u002Fsupport group program for individuals with progressive aphasia (caused by various etiologies, diagnoses) and their carepartners. The current study utilizes pre-, post-treatment, and follow-up assessments to measure effects of a psychoeducational support group and an implementation\u002Fcommunication skills training phase on measures of psychosocial function, communicative effectiveness and speech\u002Flanguage function. Analysis of study-specific surveys and semi-structured interviews will provide qualitative data regarding outcomes. Before beginning the education and support group, focus groups will be run in order to set priorities for the themes to be included in the education program. Participants will join via tele-based means if preferred and these participants may reside in the United States, or internationally including Mexico and Spain.",[59,60,27,61,62,63],"Alzheimer Disease","Dementia","Aphasia","Progressive Aphasia","Progressive Aphasia in Alzheimer's Disease",[65,66,67,68,69],"bilingual","Spanish","Castellano","multicultural","multilingual","2026-06-08",{"date":72,"type":35},"2026-06-10",{"date":74,"type":35},"2024-05-21",{"date":76,"type":21},"2030-12",{"name":78,"class":42},"University of Texas at Austin",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":51,"sex":17,"minAge":86,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":22,"phases":89,"briefSummary":90,"conditions":91,"keywords":102,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":121,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":128},"100496255","cognitive-reserve-and-response-to-speech-language-intervention-in-bilingual-speakers-with-primary-progressive-aphasia-100496255","NCT05741853","Cognitive Reserve and Response to Speech-Language Intervention in Bilingual Speakers With Primary Progressive Aphasia","Cognitive Reserve and Linguistic Resilience in Bilingual Hispanics With Primary Progressive Aphasia","Inclusion Criteria:\n\n* Meets diagnostic criteria for Primary Progressive Aphasia (PPA; Gorno-Tempini et al., 2011)\n* Bilingual in Spanish and Catalan or bilingual in Spanish and English\n* Different proficiency levels across languages are expected, any prior experience in both languages is acceptable\n* Intervention study: Score of 15 or higher on the Mini-Mental State Examination\n* Note that this project will also recruit individuals to participate in assessment only, for these individuals the following inclusion criteria applies: Score of 10 or higher on the Mini-Mental State Examination\n\nExclusion Criteria:\n\n* Other central nervous system or medical diagnosis that can cause symptoms\n* Other psychiatric diagnosis that can cause symptoms\n* Significant, uncorrected visual or hearing impairment that would interfere with participation\n* Prominent initial non-speech-language impairments (cognitive, behavioral, motoric)\n* Intervention Study: Score of less than 15 on the Mini-Mental State Examination\n* Note that this project will also recruit individuals to participate in assessment only, for these individuals the following inclusion criteria applies: Score of less than 10 on the Mini-Mental State Examination","40 Years",{"count":88,"type":21},60,[24],"Difficulties with speech and language are the first and most notable symptoms of primary progressive aphasia (PPA). While there is evidence that demonstrates positive effects of speech-language treatment for individuals with PPA who only speak one language (monolinguals), there is a significant need for investigating the effects of treatment that is optimized for bilingual speakers with PPA. This stage 2 efficacy clinical trial seeks to establish the effects of culturally and linguistically tailored speech-language interventions administered to bilingual individuals with PPA.\n\nThe overall aim of the intervention component of this study is to establish the relationships between the bilingual experience (e.g., how often each language is used, how \"strong\" each language is) and treatment response of bilinguals with PPA. Specifically, the investigators will evaluate the benefits of tailored speech-language intervention administered in both languages to bilingual individuals with PPA (60 individuals will be recruited). The investigators will conduct an assessment before treatment, after treatment and at two follow-ups (6 and 12-months post-treatment) in both languages. When possible, a structural scan of the brain (magnetic resonance image) will be collected before treatment in order to identify if brain regions implicated in bilingualism are associated with response to treatment. In addition to the intervention described herein, 30 bilingual individuals with PPA will be recruited to complete behavioral cognitive-linguistic testing and will not receive intervention. Results will provide important knowledge about the neural mechanisms of language re-learning and will address how specific characteristics of bilingualism influence cognitive reserve and linguistic resilience in PPA.",[27,60,92,59,93,94,95,96,97,98,99,100,61,101],"Dementia, Frontotemporal","Neurodegenerative Diseases","Frontotemporal Lobar Degeneration","Apraxia, Motor","Dysarthria","Communication Disorders","Language Disorders","Speech Disorders","Neurocognitive Disorders","Bilingual Aphasia",[103,104,105,27,106,107,108,109,110,111,112,113,114,115,116,117,66,67,118,119,120],"Dementia, ADRD","Bilingualism","Multilingualism","Bilingual Primary Progressive Aphasia","Cognitive Reserve","Language Decline","Bilingual Language Decline","Speech-Language Therapy","Bilingual Speech-Language Therapy","Spanish speakers","Spanish-Catalan Bilinguals","Spanish-English Bilinguals","Hispanic","Catalán","Catalan","Speech Therapy","Latino","Cognition",{"date":72,"type":35},{"date":123,"type":35},"2023-05-01",{"date":125,"type":21},"2027-11-30",{"name":127,"class":42},"Stephanie Grasso",3,{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":137,"enrollmentInfo":138,"targetDuration":4,"studyType":22,"phases":140,"briefSummary":142,"conditions":143,"keywords":144,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":43},"100530777","phase-2-communication-bridge-3-study-100530777","NCT06191198","Communication Bridge 3 Study","Communication Bridge: Optimizing an Evidence-based Intervention for Individuals With Primary Progressive Aphasia","CB3","Inclusion Criteria (person with PPA):\n\n1. Meets diagnostic criteria for PPA based on neurologist and supporting medical assessments (extracted from medical records)\n2. English as primary language used in daily communication activities (by self-report)\n3. Adequate hearing (aided or unaided) for communicating with others in a crowded room (by self-report)\n4. Adequate vision (aided or unaided) for reading a newspaper, or other functional materials (by self-report)\n5. Able to pass technology screening and demonstrates sufficient knowledge for use of video conference and Communication Bridge™ web application use (with or without training)\n6. Geriatric Depression Scale score ≤ 9\n7. Mild-moderate PPA informed by a structured interview with a speech-language pathologist and a standardized testing battery.\n\nInclusion Criteria (Co-enrolled communication partner):\n\n1. 18+ years of age\n2. English as primary language used in daily communication activities (by self-report)\n3. Adequate hearing (aided or unaided) for communicating with others in a crowded room (by self-report)\n4. Able to pass technology screening\\* and demonstrates sufficient knowledge for use of video conference and Communication Bridge™ web application use (with or without training)\n\nExclusion Criteria:\n\n* A dementia diagnosis other than Primary Progressive Aphasia\n* Participation is co-enrolled in an outside speech language therapy program during the study course.\n* Communication partners will be excluded if they have a pre-existing communication impairment that would affect study participation (e.g., aphasia, dementia)\n\nMedical records will be requested and reviewed to determine eligibility","100 Years",{"count":139,"type":21},200,[141],"PHASE2","This study will use a randomized controlled trial design to evaluate the effect of two evidence-based treatments for adults with mild-moderate Primary Progressive Aphasia (PPA). The aim of the study is to help us better understand the effects of speech-language therapy on communication abilities in individuals with PPA.",[27],[61,60,145,146,59],"Communication","Frontotemporal Dementia","2026-05-27",{"date":37,"type":35},{"date":150,"type":35},"2024-08-23",{"date":152,"type":21},"2028-07-15",{"name":154,"class":42},"University of Chicago",{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":4,"eligibilityCriteria":161,"healthyVolunteers":51,"sex":17,"minAge":162,"maxAge":163,"enrollmentInfo":164,"targetDuration":4,"studyType":22,"phases":166,"briefSummary":167,"conditions":168,"keywords":171,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":128},"100468946","phase-2-transcranial-direct-current-stimulation-in-the-treatment-of-primary-progressive-aphasia-100468946","NCT05386394","Transcranial Direct Current Stimulation in the Treatment of Primary Progressive Aphasia","Phase II Clinical Trial of Transcranial Direct Current Stimulation in the Treatment of Primary Progressive Aphasia","Inclusion Criteria:\n\n* Presence of aphasia attributable to non-fluent PPA or logopenic PPA\n* High school education (or more)\n* Between the ages of 50 and 90\n* Must be able to understand the nature of the study and give informed consent\n\nExclusion Criteria:\n\n* Cognitive impairment of sufficient severity to preclude giving informed consent (Mini Mental State Examination \\[MMSE\\] less than 15)\n* Any unrelated neurologic or physical condition that impairs communication ability\n* History of unrelated neurological conditions, including but not limited to traumatic brain injury (TBI), stroke, or small vessel disease, that has resulted in a neurologic deficit\n* Any additional neurological condition that would likely reduce the safety of study participation, including central nervous system (CNS) vasculitis, intracranial tumor, intracranial aneurysm, multiple sclerosis, or arteriovenous malformations\n* A medically unstable cardiopulmonary or metabolic disorder\n* Individuals with pacemakers or implantable cardiac defibrillators\n* Terminal illness associated with survival of less than 12 months\n* Major active psychiatric illness that may interfere with required study procedures or treatments, as determined by the enrolling physician\n* Current abuse of alcohol or drugs, prescription or otherwise\n* Participant in another drug, device, or biologics trial within 30 days prior to enrollment\n* Nursing a child, pregnant, or intending to become pregnant during the study\n* Left-handedness\n\nExclusion for tDCS, specifically:\n\n* History of spontaneous or partial complex seizures or unexplained loss of consciousness within 6 months of enrollment\n* Subjects with metallic objects in the face or head other than dental apparatus, such as braces, fillings, or implants\n* Subjects with previous craniotomy or any breach in the skull\n\nExclusion for MRI, specifically:\n\n* Presence of any of the following devices: cardiac pacemaker, other pacemakers (for carotid sinus, insulin pumps, nerve stimulators, lead wires or similar wires), optic implant, implanted cardiac defibrillator, aneurysm clip, any electronically\u002Fmagnetically\u002Fmechanically activated implant, ferromagnetic implants (coils, filters, stents; metal sutures or staples)\n* Presence of any of the following: pregnancy, claustrophobia, metal in eye or orbit, tattooed eyeliner","50 Years","90 Years",{"count":165,"type":21},180,[141],"While many have strongly suggested that transcranial direct current stimulation (tDCS) may represent a beneficial intervention for patients with primary progressive aphasia (PPA), this promising technology has not yet been applied widely in clinical settings. This treatment gap is underscored by the absence of any neurally-focused standard-of-care treatments to mitigate the devastating impact of aphasia on patients' family, work, and social lives. Given that tDCS is inexpensive, easy to use (it is potentially amenable to home use by patients and caregivers), minimally invasive, and safe there is great promise to advance this intervention toward clinical use. The principal reason that tDCS has not found wide clinical application yet is that its efficacy has not been tested in large, multi-center, clinical trials. In this study, scientists in the three sites that have conducted tDCS clinical trials in North America-Johns Hopkins University and the University of Pennsylvania in the US, and the University of Toronto in Canada, will collaborate to conduct a multi-site, Phase II clinical trial of tDCS a population in dire need of better treatments.",[27,169,170],"Logopenic Progressive Aphasia","Non-Fluent Primary Progressive Aphasia",[172,173,174],"transcranial direct current stimulation","language treatment","primary progressive aphasia","2026-04-30",{"date":177,"type":35},"2026-05-05",{"date":179,"type":35},"2024-02-13",{"date":181,"type":21},"2028-02-01",{"name":183,"class":42},"Johns Hopkins University",{"id":185,"slug":186,"hasResults":11,"nctId":187,"briefTitle":188,"officialTitle":188,"acronym":189,"eligibilityCriteria":190,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":191,"targetDuration":4,"studyType":193,"phases":4,"briefSummary":194,"conditions":195,"keywords":199,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":43},"100309796","the-neurobiology-of-two-distinct-types-of-progressive-apraxia-of-speech-100309796","NCT03313011","The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech","SLD4T","Inclusion Criteria:\n\n1. All enrolled patients must be over the age of 18, speak English as their primary language, and have an informant who can provide an independent evaluation of functioning.\n2. Each new patient must present with a chief complaint of progressive impairment of speech and must have evidence of AOS documented by a speech-language pathologist during routine clinical evaluation.\n3. At study entry, all patients must have speech sufficiently intelligible for a confident diagnosis of AOS, dysarthria, and\u002For aphasia, and for acoustic analysis.\n\nExclusion Criteria:\n\n1. Any patient whose speech is not intelligible enough for confident speech-language diagnosis will be excluded from the study.\n2. All patients with concurrent illnesses that could account for speech deficits (e.g., traumatic brain injury, strokes, developmental syndromes), and patients meeting criteria for another neurodegenerative disease (e.g., Alzheimer's type dementia57), will be excluded.\n3. Patients with aphasia or dysarthria who do not have PAOS, or whose aphasia or dysarthria at study entry is more severe than PAOS, will be excluded.\n4. All women who are pregnant, or post-partum and breast-feeding, will be excluded as they are unable to undergo the required imaging. All women who can become pregnant must have a pregnancy test no more than 48 hours before the DaTscan.\n5. Patients will also be excluded if MRI is contraindicated (e.g., metal in head, cardiac pace maker), if there is severe claustrophobia, if there are conditions that may confound brain imaging studies (e.g. structural abnormalities, including subdural hematoma or intracranial neoplasm), or if they are medically unstable or are on medications that might affect brain structure or metabolism (e.g. chemotherapy).\n6. Patients will be excluded if they do not have an informant, or do not consent to the research.",{"count":192,"type":21},47,"OBSERVATIONAL","The purpose of this study is to identify and distinguish two different types of Progressive Apraxia of Speech through clinical imaging and testing.",[196,197,27,198],"Apraxia of Speech","Non-fluent Aphasia","Primary Progressive Nonfluent Aphasia",[200],"apraxia of speech","2026-04-27",{"date":203,"type":35},"2026-05-01",{"date":205,"type":35},"2017-08-01",{"date":207,"type":21},"2027-07",{"name":209,"class":42},"Mayo Clinic",{"id":211,"slug":212,"hasResults":11,"nctId":213,"briefTitle":214,"officialTitle":215,"acronym":4,"eligibilityCriteria":216,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":217,"targetDuration":4,"studyType":193,"phases":4,"briefSummary":219,"conditions":220,"keywords":221,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":43},"100097993","language-in-primary-progressive-aphasia-100097993","NCT00537004","Language in Primary Progressive Aphasia","Asymmetric Neurodegeneration and Language in Primary Progressive Aphasia","Inclusion Criteria:\n\n* Diagnosis of primary progressive aphasia\n* Right-handed\n* Native English speaker\n* Visual acuity of 20\u002F30 corrected\n* Adequate hearing to follow conversation\n* Safe for an MRI scan\n\nExclusion Criteria:\n\n* Left-handedness\n* Claustrophobia\n* Presence of significant medical illness that initially or in the future could interfere with continued participation in the study",{"count":218,"type":21},500,"The purpose of this study is to further define the neurological and linguistic deterioration in primary progressive aphasia.",[27],[174,222,223,224,225,226],"frontotemporal dementia","semantic dementia","progressive nonfluent aphasia","progressive aphasia","frontotemporal lobar degeneration","2026-02-24",{"date":229,"type":35},"2026-02-27",{"date":231,"type":35},"2007-05",{"date":233,"type":21},"2027-04",{"name":235,"class":42},"Northwestern University",{"id":237,"slug":238,"hasResults":11,"nctId":239,"briefTitle":240,"officialTitle":240,"acronym":241,"eligibilityCriteria":242,"healthyVolunteers":11,"sex":17,"minAge":243,"maxAge":244,"enrollmentInfo":245,"targetDuration":246,"studyType":193,"phases":4,"briefSummary":247,"conditions":248,"keywords":255,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":273},"100556794","improving-prognostic-confidence-in-neurodegenerative-diseases-causing-dementia-using-peripheral-biomarkers-and-integrative-modeling-100556794","NCT06529744","Improving Prognostic Confidence in Neurodegenerative Diseases Causing Dementia Using Peripheral Biomarkers and Integrative Modeling","CRND TorCA","Inclusion Criteria:\n\n* Possible or probable diagnosis of MCI or early dementia\n* Age 30-95\n* Study partner who has some weekly contact with patient. Some of the neuropsychological assessment require collateral from close contacts to assess cognition and functioning. Since neurodegenerative diseases can be associated with reduced cognition, including reduced awareness of one's own impairments, participants will be assessed for their capacity to consent at all study visits.\n* Must, in the opinion of the site investigator, be able to complete most study procedures.\n\nExclusion Criteria:\n\n* Participants who are not able to complete the majority of assessments in the opinion of the PI are excluded from the study. Exclusion criteria are evaluated at the site investigator's discretion; if the site investigator believes that the participant's symptoms are due to causes other than neurodegeneration, despite the presence of an exclusionary condition, the investigator may overrule the exclusion.","30 Years","95 Years",{"count":218,"type":21},"1 Year","To develop a model to predict disease progression in a large cohort of patients across a variety of neurodegenerative diseases, including Mild Cognitive Impairment (MCI) and dementia due to any neurodegenerative disease, including Alzheimer's Disease (AD), Lewy Body Disease (LBD), Vascular Disease (VaD) and Frontotemporal lobar degeneration (FTLD).",[60,59,249,250,146,251,252,253,254,27],"Dementia With Lewy Bodies","Vascular Dementia","Mild Cognitive Impairment","Corticobasal Syndrome","Progressive Supranuclear Palsy","Parkinson Disease",[256,257,258,259,222,260,261,262,263,174],"alzheimer's disease","dementia","dementia with lewy bodies","vascular dementia","mild cognitive impairment","corticobasal syndrome","progressive supranuclear palsy","parkinson's disease","2025-11-17",{"date":266,"type":35},"2025-11-20",{"date":268,"type":35},"2023-11-11",{"date":270,"type":21},"2027-11",{"name":272,"class":42},"University Health Network, Toronto",4,{"id":275,"slug":276,"hasResults":11,"nctId":277,"briefTitle":278,"officialTitle":278,"acronym":4,"eligibilityCriteria":279,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":280,"targetDuration":4,"studyType":22,"phases":282,"briefSummary":284,"conditions":285,"keywords":288,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":291,"lastUpdatePostDateStruct":292,"startDateStruct":294,"completionDateStruct":296,"leadSponsor":298,"locationsCount":43},"100195328","phase-4-longitudinal-multi-modality-imaging-in-progressive-apraxia-of-speech-100195328","NCT01818661","Longitudinal Multi-Modality Imaging in Progressive Apraxia of Speech","Inclusion Criteria:\n\n* We will study subjects that fulfill clinical inclusion criteria for neurodegenerative AOS that have been seen and diagnosed at Mayo Clinic\n\nExclusion Criteria:\n\n* Subjects with concurrent illnesses that could account for speech and language deficits, such as traumatic brain injury, strokes or developmental syndromes will be excluded.\n* Women that are pregnant or post-partum and breast-feeding will be excluded. All women who can become pregnant must have a pregnancy test no more than 48 hours before the PET scan.\n* Subjects will also be excluded if MRI is contraindicated (metal in head, cardiac pace maker, e.t.c.), if there is severe claustrophobia, if there are conditions that may confound brain imaging studies (e.g. structural abnormalities, including subdural hematoma or intracranial neoplasm), or if they are medically unstable or are on medications that might affect brain structure or metabolism,(e.g. chemotherapy).\n* Subjects will also be excluded if they do not have an informant, or do not consent to research.",{"count":281,"type":21},50,[283],"PHASE4","The study is designed to determine the relationship between structural and functional changes in the brain on imaging and progression of speech and language, neurological and neuropsychological features in patients with neurodegenerative apraxia of speech (AOS).",[286,197,196,287,27],"PPA","Primary Progressive Non-fluent Aphasia",[200,289,290],"non-fluent aphasia","aphasia","2025-11-10",{"date":293,"type":35},"2025-11-12",{"date":295,"type":35},"2018-07-01",{"date":297,"type":21},"2028-06",{"name":209,"class":42},{"id":300,"slug":301,"hasResults":11,"nctId":302,"briefTitle":303,"officialTitle":304,"acronym":4,"eligibilityCriteria":305,"healthyVolunteers":51,"sex":17,"minAge":162,"maxAge":306,"enrollmentInfo":307,"targetDuration":4,"studyType":22,"phases":308,"briefSummary":309,"conditions":310,"keywords":311,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":317,"lastUpdatePostDateStruct":318,"startDateStruct":320,"completionDateStruct":322,"leadSponsor":324,"locationsCount":43},"100353868","targeting-language-specific-and-executive-control-networks-with-transcranial-direct-current-stimulation-in-logopenic-variant-ppa-100353868","NCT03887481","Targeting Language-specific and Executive-control Networks With Transcranial Direct Current Stimulation in Logopenic Variant PPA","Targeting Language-specific and Executive-control Networks With Transcranial Direct Current Stimulation in Aphasic AD (Logopenic Variant PPA)","Inclusion Criteria:\n\n* Must be between 50-80 years of age.\n* Must be right-handed.\n* Must be proficient in English.\n* Must have a minimum of high-school education.\n* Must be diagnosed with Primary Progressive Aphasia (PPA) or dementia.\n* Participants will be diagnosed with PPA or with any of the PPA variants in specialized or early dementias clinics at Johns Hopkins University or other specialized centers in the US based on the current consensus criteria.\n* Healthy age- and education-matched controls: The investigators will include 30 healthy age- and education-matched controls, usually spouses, to maximize similarity in terms of other demographic or life-style factors that contribute to language and cognitive performance.\n\nExclusion Criteria:\n\n* People with previous neurological disease including vascular dementia (e.g., stroke, developmental dyslexia, dysgraphia or attentional deficit).\n* People with uncorrected hearing loss\n* People with uncorrected visual acuity loss.\n* People with advanced dementia or severe language impairments: Mini Mental State -Examination (MMSE)\\\u003C18, or Montreal Cognitive Assessment (MOCA)\\\u003C15, or language Frontotemporal Dementia specific - Clinical Dementia Rating (FTD-CDR)\\\u003C=2.\n* Left handed individuals.\n* People with pre-existing psychiatric disorders such as behavioral disturbances, severe depression, or schizophrenia that do not allow these people to comply or follow the study schedule and requirements such as repeated evaluation and therapy.\n\nExclusion Criteria for MRI Participation:\n\n* People with severe claustrophobia.\n* People with cardiac pacemakers or ferromagnetic implants.\n* Pregnant women.","80 Years",{"count":88,"type":21},[24],"AD afflicts over 5.5. million Americans and is one of the most expensive diseases worldwide. In AD the variant in which language functions are most affected are referred to as 'logopenic variant Primary Progressive Aphasia' (lvPPA). Language deficits dramatically impair communication and quality of life for both patients and caregivers. PPA usually has an early onset (50-65 years of age), detrimentally affecting work and family life. Studies have identified verbal short-term memory\u002Fworking memory (vSTM\u002FWM) as a primary deficit and cause of language impairment. In the first cycle of this award, the investigators asked the question of whether language therapy effects could be augmented by electrical stimulation. The investigators conducted the largest to-date randomized, double-blind, sham-controlled, crossover, clinical trial to determine the effects of transcranial direct current stimulation (tDCS) in PPA. The investigators found that tDCS over the left inferior frontal gyrus (L\\_IFG), one of the major language hubs in the brain, significantly enhanced the effects of a written naming and spelling intervention. In addition, findings demonstrated that tDCS modulates functional connectivity between the stimulated area and other networks (e.g. functionally and structurally connected areas), and that tDCS modulates the inhibitory neurotransmitter gamma-aminobutyric acid (GABA). In terms of tDCS, the investigators have been identified several predictors to determine the beneficience of tDCS including (a) PPA variant, (b) initial performance on cognitive\u002Flanguage tasks, particularly vSTM\u002FWM, and (c) initial white-matter integrity and structure. These findings support the notion that tDCS benefits generalize beyond the treatment tasks and has led to the important question of the present study: How can we implement treatments to product benefits that maximally generalize to untrained but vital language\u002Fcognitive functions.\n\nTo address the above question, the investigators will test recent neuroplasticity theories that claim that the benefits of neuromodulation to language-specific areas generalize to other language functions within the language network, while neuromodulation of a domain-general\u002Fmultiple-demands area generalizes to both domain-general, executive and language functions. The two areas to be stimulated will be the supramarginal gyrus (SMG) and left dorsolateral prefrontal cortex (DLPFC) respectively. The left supramarginal gyrus (L\\_SMG) in particular, specializes in phonological processing, namely phonological verbal short-term memory (vSTM), i.e., the ability to temporarily store phonological (and graphemic) information in order. The domain of vSTM affects many language tasks (repetition, naming, syntax), which makes it an ideal treatment target and the L\\_SMG an ideal stimulation target, since generalization of tDCS effects to other language tasks is driven by the function (computation) of the stimulated area. By testing a fundamental principle of neuromodulation in a devastating neurodegenerative disorder, the investigators will significantly advance the field of neurorehabilitation in early-onset dementias.\n\nAim 1: To determine whether vSTM\u002FWM behavioral therapy combined with high definition (HD)-tDCS over the L\\_SMG will induce more generalization to language-specific tasks than to executive tasks, whereas stimulation over the LDPFC will induce equivalent generalization to both executive and language-specific tasks.\n\nAim 2: To understand the mechanism of tDCS by measuring tDCS-induced changes in network functional connectivity (FC) and GABA in the LSMG and LDPFC. The investigators will carry out resting-state functional magnetic resonance imaging (rsfMRI), (MPRAGE), diffusion-weighted imaging (DWI), perfusion imaging (pCASL), and magnetic resonance spectroscopy (MRS), before, after, and 3-months post-intervention.\n\nAim 3: To identify the neural, cognitive, physiological, clinical and demographic characteristics (biomarkers) that predict sham, tDCS, and tDCS vs. sham effects on vSTM and related language tasks in PPA. The investigators will evaluate neural (functional and structural connectivity, cortical volume, neuropeptides, and perfusion), cognitive (memory, attention, executive) and language functions, clinical (severity), physiological (sleep), and demographic (age, gender) characteristics, and the investigators will analyze the effects on vSTM and other language\u002Fcognitive outcomes immediately after intervention and at 3 months post-intervention.",[169,27],[312,313,314,315,316,174],"transcranial direct current stimulation (tDCS)","neurodegeneration","verbal short-term memory","non-fluent variant","logopenic variant","2025-09-08",{"date":319,"type":35},"2025-09-15",{"date":321,"type":35},"2022-10-15",{"date":323,"type":21},"2027-10-31",{"name":183,"class":42},{"id":326,"slug":327,"hasResults":11,"nctId":328,"briefTitle":329,"officialTitle":330,"acronym":331,"eligibilityCriteria":332,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":333,"targetDuration":4,"studyType":22,"phases":335,"briefSummary":336,"conditions":337,"keywords":341,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":347,"lastUpdatePostDateStruct":348,"startDateStruct":350,"completionDateStruct":352,"leadSponsor":354,"locationsCount":356},"100496320","phase-2-nabilone-for-agitation-in-frontotemporal-dementia-100496320","NCT05742698","Nabilone for Agitation in Frontotemporal Dementia","Double Blind Crossover Clinical Trial of Nabilone for Agitation in Frontotemporal Dementia","Nabilone-FTD","Inclusion Criteria:\n\n* Men and women over 18 years\n* Major neurocognitive disorder due to probable behavioural variant FTD (Rascovsky criteria)17 or primary progressive aphasia (Gorno-Tempini criteria)18. All ages and severity levels will be included.\n* Meets International Psychogeriatric Association criteria for agitation in cognitive disorders19\n* CMAI score of 39 or above\n* Stable psychoactive medication for 2 weeks prior to screening (all medications allowed) with no intention to change dose during treatment period\n* Available study partner with ≥10 hours per week in-person contact with the patient. This can either be a friend\u002Ffamily member or a staff member at an assisted living facility.\n* Capacity to provide written consent in English or French, or consent from official surrogate decision maker in case of incapacity\n\nRationale for Inclusion Criteria: The inclusion criteria are designed to enroll patients with FTD with the behaviours of interest, with a range of disease severity that will permit assessment of all outcome measures.\n\nExclusion Criteria:\n\n* Clinically significant psychotic symptoms (Neuropsychiatric Inventory domain score (severity x frequency) ≥4 on the delusions or hallucinations subscale)\n* Clinically significant orthostatic hypotension (a decrease in systolic blood pressure of 20 mm Hg or in diastolic blood pressure of 10 mm Hg within three minutes of standing compared to blood pressure in a seated position)\n* Symptomatic orthostatic tachycardia (heart rate increase from of at least 30 beats per minute within the first 5 minutes of standing compared to a seated position IF orthostatic hypotension is not a problem)\n* Unstable cardiovascular condition in the opinion of the investigator\n* Known or suspected history of drug or alcohol dependence or abuse in the past 12 months, including use of any psychomimetic drugs (e.g. ketamine, lysergic acid diethylamide, psilocybin).\n* Allergy, or significant adverse reaction to cannabinoids. If the adverse reaction involved psychological symptoms that are indicative of psychosis or severe anxiety the patient will be excluded. Their treating clinician may be consulted for a clinical opinion on the severity of the response to cannabis and whether this justifies exclusion from the trial.\n* Major depressive episode within 6 months of screening\n* Women who are breast feeding or pregnant\n* Severe liver dysfunction, as determined by their treating clinician\n* Other psychiatric or neurological condition that could cause significant agitation\n* Ongoing use of any cannabinoid-related products. This includes any THC or CBD based products, regardless of administration method (oral, inhalation, topical, etc…)\n\nRationale for Exclusion Criteria: The exclusion criteria are designed to avoid inclusion of patients who may have medical comorbidities that would increase their risk of serious side effects from repeated nabilone administration.",{"count":334,"type":21},45,[141],"The primary goal of this study is to test the hypothesis that oral nabilone treatment will reduce agitation compared with placebo in patients with Frontotemporal Dementia (both behavioural variant frontotemporal dementia and primary progressive aphasia). The study population is defined as patients with probable Frontotemporal Dementia that meet the International Psychogeriatric Association criteria for agitation in cognitive disorders.",[146,338,27,339,286,340],"Frontotemporal Dementia, Behavioral Variant","bvFTD","FTD",[342,343,344,345,60,346,340],"Nabilone","Nabilone FTD","Agitation","TEVA Nabilone","BvFTD","2025-04-11",{"date":349,"type":35},"2025-04-15",{"date":351,"type":35},"2023-03-07",{"date":353,"type":21},"2026-05",{"name":355,"class":42},"Simon Ducharme, MD",7,{"id":358,"slug":359,"hasResults":11,"nctId":360,"briefTitle":361,"officialTitle":362,"acronym":4,"eligibilityCriteria":363,"healthyVolunteers":51,"sex":17,"minAge":364,"maxAge":306,"enrollmentInfo":365,"targetDuration":4,"studyType":22,"phases":367,"briefSummary":368,"conditions":369,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":372,"lastUpdatePostDateStruct":373,"startDateStruct":375,"completionDateStruct":377,"leadSponsor":379,"locationsCount":43},"100473341","enhancing-language-function-in-aphasia-100473341","NCT05443633","Enhancing Language Function in Aphasia","Enhancing Language Function in Aphasia Using Behavioral Language Intervention","Inclusion Criteria:\n\n1. Present with speech-language impairment (aphasia) caused by stroke or dementia\n2. A medical diagnosis of primary progressive aphasia (PPA) by a neurologist or physician\n3. Are native speakers of English\n4. Present with no contraindications for MRI\n5. Have adequate (normal or corrected to normal) vision and hearing\n\nExclusion Criteria:\n\n1. Individuals diagnosed with mood, anxiety, psychotic or substance abuse disorders.\n2. Individuals with highly magnetizable metallic implants, including certain dental work, may be excluded due to image quality in MRI.\n3. Individuals with other neurological disorders besides the ones of interest for the study (e.g., epilepsy, Multiple Sclerosis, Parkinson's Disease)\n4. Individuals with contraindications for MRI. This includes but is not limited to pacemakers, metallic cardiac pumps, valves, magnetic materials such as surgical clips, implanted electronic perfusion pumps, or any other condition that would preclude proximity to a strong magnetic field.\n5. Individuals suffering from clinically significant claustrophobia\n6. Severe systemic disease (e.g., renal failure)\n7. Poor overall health\n8. Individuals who are pregnant\n9. Individuals with a history of epileptic activity in the past 12 months\n10. Individuals with a personal or family history of epilepsy or other seizure disorders will not be included in the study.\n11. Individuals who have had a brain surgery in the past\n12. Individuals with implanted metallic skull plates or intracranial implants\n13. Individuals with skin lesions or skull damage\n14. Individuals who have a history of excessive use of alcohol or drugs\n15. Individuals with premorbid psychiatric disease affecting communication\n16. Individuals with severe non-linguistic cognitive disturbances impeding language therapy","21 Years",{"count":366,"type":21},30,[24],"Aphasia is an acquired impairment of language, that commonly results from damage to language areas in the brain (typically the left side of the brain). This impairment is seen in many aspects of language, including understanding, speaking, reading and writing. It is estimated that about 2 million individuals are currently living with aphasia in the United States. Further, about 200,000 Americans acquire aphasia every year (National Aphasia Association, 2020). Aphasia poses significant impact on the affected individuals and their families. Behavioral treatments that target language deficits have been shown to enhance overall communication skills and life satisfaction among individuals with aphasia. Although there is evidence that suggests that treatment is efficacious for individuals with aphasia, the extent of improvement long-term coupled with the neural patterns among those individuals are largely unknown. The current study aims to investigate the efficacy of language-based treatment and its corresponding neural patterns.",[370,98,27,371],"Aphasia, Acquired","Stroke, Cerebrovascular","2024-12-04",{"date":374,"type":35},"2024-12-09",{"date":376,"type":35},"2022-10-30",{"date":378,"type":21},"2028-12-15",{"name":380,"class":42},"University of Arizona",{"id":382,"slug":383,"hasResults":11,"nctId":384,"briefTitle":385,"officialTitle":386,"acronym":286,"eligibilityCriteria":387,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":306,"enrollmentInfo":388,"targetDuration":4,"studyType":22,"phases":389,"briefSummary":390,"conditions":391,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":392,"lastUpdatePostDateStruct":393,"startDateStruct":395,"completionDateStruct":397,"leadSponsor":399,"locationsCount":43},"100433145","enhancing-language-function-in-primary-progressive-aphasia-100433145","NCT04920318","Enhancing Language Function in Primary Progressive Aphasia","Enhancing Language Function in Primary Progressive Aphasia (PPA) With Transcranial Direct Current Stimulation (tDCS)","Inclusion Criteria:\n\n* diagnosed with PPA by neurologist or speech-language pathologist\n* speech-language deficit arising from PPA\n* native speaker of English Language or equivalent\n* adequate vision (normal or corrected to normal)\n* adequate hearing\n\nExclusion Criteria:\n\n* meeting (Diagnostic and Statistical Manual) DSM-IV criteria for Axis I mood, anxiety, psychotic or substance abuse disorders.\n* highly magnetizable metallic implants, including certain dental work\n* neurological disorders besides the ones of interest for the study (e.g., epilepsy)\n* Multiple Sclerosis\n* Parkinson's Disease\n* contraindications for MRI\n* pacemakers\n* metallic cardiac pumps\n* valves\n* magnetic materials such as surgical clips, implanted electronic perfusion pumps, or any other condition that would preclude proximity to a strong magnetic field.\n* clinically significant claustrophobia\n* severe systemic disease (e.g., renal failure)\n* poor health\n* pregnancy\n* epileptic activity in the past 12 months\n* family history of epilepsy or other seizure disorders\n* brain surgery in the past\n* metallic skull plates or implants\n* skin lesions or skull damage\n* excessive use of alcohol or drugs\n* premorbid psychiatric disease affecting communication\n* severe non-linguistic cognitive disturbances impeding language therapy",{"count":20,"type":21},[24],"This study's goal is to use non-invasive brain stimulation (NBS) techniques to treat language impairment associated with Primary Progressive Aphasia (PPA). The purpose of this study is to combine behavioral language intervention with individualized noninvasive brain stimulation techniques, called transcranial direct current stimulation (tDCS) to help the brain reorganize around damage and improve language functions.",[27],"2024-11-26",{"date":394,"type":35},"2024-11-29",{"date":396,"type":35},"2021-08-30",{"date":398,"type":21},"2027-06-15",{"name":380,"class":42},{"id":401,"slug":402,"hasResults":11,"nctId":403,"briefTitle":404,"officialTitle":404,"acronym":405,"eligibilityCriteria":406,"healthyVolunteers":11,"sex":17,"minAge":86,"maxAge":4,"enrollmentInfo":407,"targetDuration":4,"studyType":22,"phases":408,"briefSummary":409,"conditions":410,"keywords":411,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":414,"lastUpdatePostDateStruct":415,"startDateStruct":417,"completionDateStruct":419,"leadSponsor":421,"locationsCount":273},"100495349","a-multimodal-approach-for-clinical-diagnosis-and-treatment-of-primary-progressive-aphasia-mainstream-id3430931-100495349","NCT05730023","A Multimodal Approach for Clinical Diagnosis and Treatment of Primary Progressive Aphasia, MAINSTREAM ID:3430931","MAINSTREAM","Inclusion Criteria:\n\n* Diagnosis PPA according to the current clinical criteria (Gorno-Tempini et al., 2011);\n* Mild PPA defined using the Progressive Aphasia Severity Scale (PASS);\n* Italian native speakers.\n\nExclusion Criteria:\n\n* Presence of developmental disorders;\n* Presence of any medical or psychiatric illness that could interfere in completing assessments;\n* Presence of any medical condition that represents a contraindication to tDCS.",{"count":88,"type":21},[24],"Primary Progressive Aphasia (PPA) is a syndrome due to different neurodegenerative disorders selectively disrupting language functions. PPA specialist care is underdeveloped. There are very few specialists (neurologists, psychiatrists, neuropsychologists and speech therapists) and few hospitals- or community-based services dedicated to diagnosis and continuing care. Currently, healthcare systems struggle to provide adequate coverage of diagnostic services, and care is too often fragmented, uncoordinated, and unresponsive to the needs of people with PPA and their families. Recently attention has been gained by digital-health technologies, such immunoassay analyzer and high-field MRI, the most promising approaches to increase our understanding of neurodegeneration, and by new non-invasive brain stimulation techniques such as transcranial direct current stimulation (tDCS) that allow a personalized treatment approach. Our goal is to develop a new treatment approach in PPA in which the regional secondary care centers participating in this project should be the hub of a regional network. The MAINSTREAM (WP2- Efficacy of personalized training in the early stage of PPA) looks forward to introduce and evaluate therapeutic innovation such as tDCS coupled with language therapy in rehabilitation settings (WP2 Early Treatment).\n\nThis objective will be pursued by conducting a randomized controlled pilot study in order to evaluate the efficacy of a combined treatment of Active (anodal) tDCS and individualized language training compared to Placebo tDCS combined with individualized language training in a subgroup of mild PPA defined using the Progressive Aphasia Severity Scale (PASS) (Sapolsky D, Domoto-Reilly K, Dickerson BCJA. Use of the Progressive Aphasia Severity Scale (PASS) in Monitoring Speech and Language Status in PPA. (2014) 28(8-9):993-1003).",[27],[412,413],"Behavioral and neural effects of tDCS combined with language training","Alzheimer's disease and other dementias","2024-09-06",{"date":416,"type":35},"2024-09-19",{"date":418,"type":35},"2023-02-01",{"date":420,"type":21},"2026-02",{"name":422,"class":42},"IRCCS Centro San Giovanni di Dio Fatebenefratelli",{"id":424,"slug":425,"hasResults":11,"nctId":426,"briefTitle":427,"officialTitle":428,"acronym":429,"eligibilityCriteria":430,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":137,"enrollmentInfo":431,"targetDuration":4,"studyType":22,"phases":432,"briefSummary":433,"conditions":434,"keywords":435,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":445,"lastUpdatePostDateStruct":446,"startDateStruct":448,"completionDateStruct":450,"leadSponsor":452,"locationsCount":43},"100436000","semantic-rehabilitation-for-patients-with-primary-progressive-semantic-aphasia-100436000","NCT04957537","Semantic Rehabilitation for Patients With Primary Progressive Semantic Aphasia","Evaluation of the Effect of a Semantic Rehabilitation in Patients in the Mild to Moderate Stage of Primary Progressive Semantic Aphasia : a SCED Study","SCED-APPvs","Inclusion Criteria:\n\n* Have a diagnosis of primary progressive semantic aphasia according to the criteria of Gorno-Tempini et al (2011) (Appendix A)\n* Being in the mild to moderate stage of dementia (MMSE score between 10 and 28) (Crum et al., 1993; Derouesné et al., 1999)\n* Common French\n* Being affiliated to a social security scheme\n* Being over the age of 18 years old\n\nExclusion Criteria:\n\n* Have significant uncorrected visual and\u002For hearing impairment\n* Have a history of brain injuries, major head trauma\n* Have untreated psychiatric disorders\n* Have significant motor and\u002For comprehension problems that make it impossible to take part in the study\n* Chronical use of drugs and\u002For alcohol\n* Under guardians or curators\n* Severe depression (Beck's depression scale score \\> 9) (Beck \\& al., 1961)",{"count":5,"type":21},[24],"This project aims to measure the effect of a semantic rehabilitation protocol for patients with primary progressive semantic aphasia and using the SCED methodology.",[27],[436,437,438,439,440,441,442,443,444],"Semantic primary progressive aphasia","semantic variant (svPPA)","speech therapy","anomia","metacognition","Single Case Experimental Design","technology","naming","speed of lexical access","2024-08-01",{"date":447,"type":35},"2024-08-02",{"date":449,"type":35},"2021-09-20",{"date":451,"type":21},"2025-09",{"name":453,"class":42},"University Hospital, Toulouse"]